Salvatore Grisanti1, Deborah Cosentini1, Valeria Tovazzi1, Susanna Bianchi1, Barbara Lazzari1, Francesca Consoli1, Elisa Roca1, Alfredo Berruti2,3, Vittorio D Ferrari1. 1. Dipartimento di Specialità Medico-Chirurgiche, Scienze Radiologiche e Sanità Pubblica, Oncologia Medica, Università degli Studi di Brescia, ASST Spedali Civili, Brescia, Italy. 2. Dipartimento di Specialità Medico-Chirurgiche, Scienze Radiologiche e Sanità Pubblica, Oncologia Medica, Università degli Studi di Brescia, ASST Spedali Civili, Brescia, Italy. alfredo.berruti@gmail.com. 3. Oncologia Medica, ASST Spedali Civili, Piazzale Spedali Civili 1, 20123, Brescia, Italy. alfredo.berruti@gmail.com.
Abstract
PURPOSE: Trabectedin is one of the few active agents in soft tissue sarcoma (STS) but hepatotoxicity is frequent and represents a dose-limiting factor. Protective strategies aiming at counteracting this important side effect have a crucial clinical impact. Due to its antioxidant properties, N-acetylcysteine (NAC) has a recognized hepatoprotective effect and this provides the rationale for testing NAC in the management of trabectedin-induced hepatotoxicity. METHODS: Patients with recurrent or metastatic soft tissue sarcoma, consecutively observed at our institution, who were considered eligible to trabectedin, received concomitant NAC if they had impaired hepatic or renal function at baseline or developed hepatotoxicity during treatment. The study aim was to retrospectively explore trabectedin administration in terms of number of cycles, mean dose, and dose intensity (DI) in patients who received NAC as compared with those who did not. Secondary end points were progression-free survival (PFS) and overall survival (OS). RESULTS: A total number of 18 patients were enrolled in this study. Nine received NAC and nine did not. The median number of administered trabectedin cycles, mean trabectedin dose/cycles, and median DI was comparable in the two groups (p = 0.450, p = 0.534, and p = 0.450, respectively). The PFS and OS curves overlapped. CONCLUSION: This explorative study suggests that NAC can have a hepatoprotective activity in patients receiving trabectedin allowing to maintain an adequate dose intensity and continuative administration in patients with impaired liver and renal function or developing treatment-induced hepatotoxicity. A prospective randomized trial is warranted.
PURPOSE:Trabectedin is one of the few active agents in soft tissue sarcoma (STS) but hepatotoxicity is frequent and represents a dose-limiting factor. Protective strategies aiming at counteracting this important side effect have a crucial clinical impact. Due to its antioxidant properties, N-acetylcysteine (NAC) has a recognized hepatoprotective effect and this provides the rationale for testing NAC in the management of trabectedin-induced hepatotoxicity. METHODS:Patients with recurrent or metastatic soft tissue sarcoma, consecutively observed at our institution, who were considered eligible to trabectedin, received concomitant NAC if they had impaired hepatic or renal function at baseline or developed hepatotoxicity during treatment. The study aim was to retrospectively explore trabectedin administration in terms of number of cycles, mean dose, and dose intensity (DI) in patients who received NAC as compared with those who did not. Secondary end points were progression-free survival (PFS) and overall survival (OS). RESULTS: A total number of 18 patients were enrolled in this study. Nine received NAC and nine did not. The median number of administered trabectedin cycles, mean trabectedin dose/cycles, and median DI was comparable in the two groups (p = 0.450, p = 0.534, and p = 0.450, respectively). The PFS and OS curves overlapped. CONCLUSION: This explorative study suggests that NAC can have a hepatoprotective activity in patients receiving trabectedin allowing to maintain an adequate dose intensity and continuative administration in patients with impaired liver and renal function or developing treatment-induced hepatotoxicity. A prospective randomized trial is warranted.
Authors: Hartmut Jaeschke; Gregory J Gores; Arthur I Cederbaum; Jack A Hinson; Dominique Pessayre; John J Lemasters Journal: Toxicol Sci Date: 2002-02 Impact factor: 4.849
Authors: F Grosso; P Dileo; R Sanfilippo; S Stacchiotti; R Bertulli; C Piovesan; J Jimeno; M D'Incalci; A Gescher; P G Casali Journal: Eur J Cancer Date: 2006-06-05 Impact factor: 9.162
Authors: Ibrahim Sales; Amy L Dzierba; Pamela L Smithburger; Deanna Rowe; Sandra L Kane-Gill Journal: Ann Hepatol Date: 2013 Jan-Feb Impact factor: 2.400
Authors: George D Demetri; Margaret von Mehren; Robin L Jones; Martee L Hensley; Scott M Schuetze; Arthur Staddon; Mohammed Milhem; Anthony Elias; Kristen Ganjoo; Hussein Tawbi; Brian A Van Tine; Alexander Spira; Andrew Dean; Nushmia Z Khokhar; Youn Choi Park; Roland E Knoblauch; Trilok V Parekh; Robert G Maki; Shreyaskumar R Patel Journal: J Clin Oncol Date: 2015-09-14 Impact factor: 44.544
Authors: George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: José María del Campo; Cristiana Sessa; Carolyn N Krasner; Jan B Vermorken; Nicoletta Colombo; Stan Kaye; Martin Gore; Patrik Zintl; Javier Gómez; Trilok Parekh; Youn Choi Park; Scott McMeekin Journal: Med Oncol Date: 2013-02-09 Impact factor: 3.064